Stoke Therapeutics, Inc. (STOK) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| EMPEROR Phase 3 Patients Randomized (Approximately) | 130.00 | FY2026-Q1 |
| Collaboration Revenue Recognized (Biogen) | 3.2M | FY2025-Q2 |
| Collaboration Revenue Recognized from Upfront License Fees and Services (Acadia Pharmaceuticals) | 6.1M | FY2025-Q1 |
Back to STOK overview · STOK earnings · STOK holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.